Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H21N |
Molecular Weight | 155.2804 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(C)(C)CCCC1(C)C
InChI
InChIKey=XULIXFLCVXWHRF-UHFFFAOYSA-N
InChI=1S/C10H21N/c1-9(2)7-6-8-10(3,4)11(9)5/h6-8H2,1-5H3
Molecular Formula | C10H21N |
Molecular Weight | 155.2804 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/29010Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/13584741 | https://www.ncbi.nlm.nih.gov/pubmed/5994381 | https://www.ncbi.nlm.nih.gov/pubmed/13618559 | https://www.ncbi.nlm.nih.gov/pubmed/22290370
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29010
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/13584741 | https://www.ncbi.nlm.nih.gov/pubmed/5994381 | https://www.ncbi.nlm.nih.gov/pubmed/13618559 | https://www.ncbi.nlm.nih.gov/pubmed/22290370
Pempidine is a nicotinic antagonist most commonly used as an experimental tool. It has been used as a ganglionic blocker in the treatment of hypertension but has largely been supplanted for that purpose by more specific drugs. In preclinical models Pempidine blocks the effects of intravenous nicotine and of peripheral vagal stimulation on the blood pressure; it also causes dilatation of the pupil after removal of the sympathetic innervation. On the guinea-pig ileum, the predominant effect of the compound is to inhibit nicotine contractions. Pempidineis well absorbed from the gastrointestinal tract as judged by (a) the low ratio (6.9) of oral to intravenous toxicities, (b) the rapid development of mydriasis in mice after oral administration of small doses, and (c) the rapid onset of hypotension when the compound is injected directly into the duodenum of anaesthetized cats. Other actions include neuromuscular paralysis of curare-like type when large doses of the compound are injected intravenously and central effects such as tremors which occur with near toxic doses. In cats with a low blood pressure, large intravenous doses have a slight pressor action.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2366189 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg 4 times / day multiple, oral Studied dose Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Gastrointestinal disorder, Ileus... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (50%) Sources: Ileus (grade 3, 20%) Constipation (grade 3, 20%) Vomiting (grade 3, 20%) Urinary retention (10%) Ileus (grade 5, 10%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Urinary retention | 10% Disc. AE |
15 mg 4 times / day multiple, oral Studied dose Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Gastrointestinal disorder | 50% Disc. AE |
15 mg 4 times / day multiple, oral Studied dose Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Constipation | grade 3, 20% Disc. AE |
15 mg 4 times / day multiple, oral Studied dose Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Ileus | grade 3, 20% Disc. AE |
15 mg 4 times / day multiple, oral Studied dose Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Vomiting | grade 3, 20% Disc. AE |
15 mg 4 times / day multiple, oral Studied dose Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Ileus | grade 5, 10% Disc. AE |
15 mg 4 times / day multiple, oral Studied dose Dose: 15 mg, 4 times / day Route: oral Route: multiple Dose: 15 mg, 4 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 7.9433 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
yes [Inhibition 10 uM] | ||||
yes [Inhibition 10 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Optimization of palladium-catalyzed polyene cyclizations: suppression of competing hydride transfer from tertiary amines with Dabco and an unexpected hydride transfer from 1,4-dioxane. | 2001 Jan 25 |
|
Spirocyclic zwitterionic lambda5Si-silicates with two bidentate ligands derived from alpha-amino acids or alpha-hydroxycarboxylic acids: synthesis, structure, and stereodynamics. | 2004 Nov 10 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13618559
LD50 for the HCl salt of pempidine in mice: 74 mg/kg (i.v.); 125 mg/kg (i.p.); 413 mg/kg (p.o.).
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:02:12 GMT 2025
by
admin
on
Mon Mar 31 18:02:12 GMT 2025
|
Record UNII |
N5I18JI9D6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66886
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000082477
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
N5I18JI9D6
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
Pempidine
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
D010393
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
6603
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
C66335
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
79-55-0
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL1617409
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
758448
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
DTXSID7046962
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
SUB09658MIG
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
831
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
m8459
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | Merck Index | ||
|
2076
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY | |||
|
201-211-2
Created by
admin on Mon Mar 31 18:02:12 GMT 2025 , Edited by admin on Mon Mar 31 18:02:12 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |